Comparative Pharmacology
Head-to-head clinical analysis: ELFABRIO versus KANUMA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ELFABRIO versus KANUMA.
ELFABRIO vs KANUMA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Recombinant human α-galactosidase A enzyme that hydrolyzes globotriaosylceramide (Gb3) and other glycosphingolipids with terminal α-galactosyl groups, thereby reducing accumulation in tissues.
Recombinant human lysosomal acid lipase (LAL) that catalyzes the hydrolysis of cholesteryl esters and triglycerides in lysosomes.
1 mg/kg intravenously over 2 hours every 2 weeks.
1 mg/kg intravenously over 4 hours once weekly.
None Documented
None Documented
Terminal elimination half-life approximately 0.5–1 hour; short half-life necessitates twice-weekly intravenous dosing.
Terminal elimination half-life: approximately 2–5 hours (range 1.5–7.5 hours) in patients with LAL deficiency. Clinical context: half-life supports weekly intravenous dosing.
Primarily eliminated via renal excretion as intact protein; minimal biliary/fecal elimination (<1%).
Primarily cleared via receptor-mediated endocytosis and lysosomal degradation; negligible renal or biliary/fecal elimination of active drug. <1% excreted unchanged in urine.
Category C
Category C
Enzyme Replacement Therapy
Enzyme Replacement Therapy